Why Is AMGEN INC (AMGN) Stock Moving Today?

Amgen Inc (AMGN) shares fell 10.08% to $393.17 in a session marked by investor concern over the future of its cholesterol-lowering drug olpasiran. The decline followed Novartis’ announcement of a failed Phase 3 trial for its competing drug pelacarsen, which raised doubts about the broader Lp(a) drug class. Despite Amgen releasing positive results from a late-stage lung cancer trial with AstraZeneca, the market focused on the negative implications for its cholesterol portfolio.

What Happened

The primary driver of the sell-off was Novartis’ Phase 3 trial failure for pelacarsen, which has created uncertainty about olpasiran’s potential. Amgen’s stock dropped significantly as investors reevaluated the risk of regulatory or commercial setbacks for its high-conviction asset. The market also appeared to discount Amgen’s positive lung cancer data, which showed that its drug Imdelltra in combination with AstraZeneca’s Imfinzi extended survival in a late-stage trial. However, this news could not offset the broader negative sentiment. BMO Capital Markets also downgraded Amgen following the Novartis news, adding pressure to the stock. The session saw heightened volatility, with Amgen shares falling to a 52-week low of $395.11 after an 8-session decline of 10.1%.

What The Data Shows

The stock’s intraday performance reflected a sharp sell-off, with volume expected to exceed its 30-day average. Over the past 30 days, sentiment has deteriorated from an average of 55/100 to 48/100. Recent insider transactions show three executives sold a combined $4.1 million in shares over the last 90 days. On the 52-week tape, the stock printed 42 fresh 52-week lows but also one fresh high on 2026-09-08. Congressional trades also included several sales of AMGN shares, with the most recent disclosed on 2026-09-05.

What To Watch

Investors will look to Amgen’s upcoming corporate actions, including its dividend schedule set for ex-dividend on 2026-08-21. The focus will remain on olpasiran’s regulatory path and how the market reacts to further data or competitor developments in the Lp(a) space.

Why is AMGN stock moving today?

AMGEN INC (AMGN) is drawing unusual attention today. Our newswire has captured 15 stories on AMGN across 8 sources in the last 36 hours, with AI sentiment reading mixed (avg 51/100). The most recent driver: "Amgen (AMGN) Maintains Quarterly Dividend at $2.52 with 2.25% Yield" (GuruFocus).

Is AMGN a buy right now?

Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of AMGN coverage reads 51/100 over 15 stories; treat it as a research signal and do your own diligence.

How fast does this page update?

The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.